U266B1細胞 
	
		運輸方式:	凍存運輸
	
	
		細胞形態(tài):	**樣
	
	
		**類型:	IgE; lambda light chain
	
	
		年限:	53 years *****
	
	
		ATCC Number:	TIB-196?
	
	
		相關**:	其他**
	
	
		器官來源:	外周血
	
	
		細胞類型:	B**細胞
	
	
		數(shù)量:	大量
	
	
		是否是腫瘤細胞:	1
	
	
		物種來源:	人
	
	
		生長狀態(tài):	懸浮生長
	
	
		U266B1細胞Designations:	U266B1 [U266]
	
	
		Depositors:	 NK Nilsson
	
	
		Isotype:	IgE; lambda light chain
	
	
		Biosafety Level:	1
	
	
		Shipped:	frozen
	
	
		Medium & Serum:	See Propagation
	
	
		Growth Properties:	suspension
	
	
		Organism:	Homo sapiens
	
	
		Morphology:	lymphoblast
	
	
		
	
	
		Source:	Organ: peripheral blood
	
	
		Disease: myeloma; plasmacytoma
	
	
		Cell Type: B lymphocyte;
	
	
		Cellular Products:	immunoglobulin; monoclonal antibody; interleukin 6 (interleukin-6, IL-6)
	
	
		Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. U266B1細胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
	
	
		Applications:	transfection host
	
	
		DNA Profile (STR):	Amelogenin: X,Y
	
	
		CSF1PO: 12,13
	
	
		D13S317: 12
	
	
		D16S539: 10
	
	
		D5S818: 11,12
	
	
		D7S820: 11,12
	
	
		THO1: 5,7
	
	
		TPOX: 8
	
	
		vWA: 17
	
	
		Age:	53 years *****
	
	
		Gender:	male
	
	
		Comments:	U266 cells have been reported to produce human IL-6.
	
	
		Propagation:	ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
	
	
		Subculturing:	Medium Renewal: Every 2 to 3 days
	
	
		Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml.
	
	
		Preservation: U266B1細胞culture medium 95%; DMSO, 5%
	
	
		Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
	
	
		recommended serum:ATCC 30-2020
	
	
		References:	1180: Nilsson K, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745
	
	
		22377: Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988. PubMed: 3258060
	
	
		32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. U266B1細胞PubMed: 8706128